News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
462,856 Results
Type
Article (26314)
Company Profile (116)
Press Release (436419)
Multimedia
Podcasts (116)
Webinars (10)
Section
Business (149416)
Career Advice (503)
Deals (22313)
Drug Delivery (68)
Drug Development (43877)
Employer Resources (62)
FDA (11048)
Job Trends (8903)
News (210087)
Policy (16395)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Standard (4)
2027 Pharm Country Standard (5)
Academia (1776)
Academic (1)
Accelerated approval (37)
ADA (22)
Adcomms (11)
Allergies (118)
Alliances (39880)
ALS (110)
Alzheimer's disease (1005)
Antibody-drug conjugate (ADC) (364)
Approvals (11484)
Artificial intelligence (711)
ASCO (158)
Autoimmune disease (227)
Automation (60)
Bankruptcy (153)
Best Places to Work (7397)
BIO (47)
Biologics (2)
BIOSECURE Act (9)
Biosimilars (138)
BioSpace Insights (119)
Biotechnology (93)
Bladder cancer (115)
Brain cancer (52)
Breast cancer (466)
Cancer (4074)
Cardiovascular disease (300)
Career advice (486)
Career pathing (17)
CAR-T (313)
CDC (17)
Celiac Disease (2)
Cell therapy (847)
Cervical cancer (38)
Clinical research (37639)
Collaboration (1975)
Commercialization (5)
Company closure (3)
Compensation (509)
Complete response letters (46)
COVID-19 (1664)
CRISPR (131)
C-suite (942)
Cystic fibrosis (126)
Data (5424)
Decentralized trials (2)
Denatured (38)
Depression (82)
Dermatology (56)
Diabetes (366)
Diagnostics (6172)
Digital health (58)
Diversity (7)
Diversity, equity & inclusion (12)
Drug discovery (315)
Drug pricing (40)
Drug shortages (6)
Duchenne muscular dystrophy (296)
Earnings (50536)
Editorial (28)
Employer branding (10)
Employer resources (59)
Events (66627)
Executive appointments (786)
FDA (13950)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (22)
Funding (1380)
Gene editing (286)
Generative AI (57)
Gene therapy (886)
GLP-1 (457)
Government (1793)
Grass and pollen (3)
Guidances (277)
Healthcare (11629)
Hematology (106)
HIV (50)
Huntington's disease (52)
IgA nephropathy (67)
Immunology and inflammation (125)
Immuno-oncology (58)
Indications (137)
Infectious disease (1906)
Inflammatory bowel disease (124)
Inflation Reduction Act (6)
Influenza (103)
Intellectual property (248)
Interviews (62)
IPO (9581)
IRA (12)
Job creations (1804)
Job search strategy (422)
JPM (35)
Kidney cancer (13)
Labor market (36)
Layoffs (235)
Leadership (11)
Legal (3514)
Licensing (10)
Liver cancer (68)
Longevity (23)
Lung cancer (543)
Lymphoma (322)
Machine learning (56)
Management (20)
Manufacturing (964)
Marketing (6)
MASH (75)
Medical device (12350)
Medtech (12584)
Mergers & acquisitions (13740)
Metabolic disorders (770)
mRNA (215)
Multiple sclerosis (106)
NASH (5)
Neurodegenerative disease (294)
Neuropsychiatric disorders (38)
Neuroscience (1951)
NextGen: Class of 2026 (3901)
Non-profit (1882)
Now hiring (28)
Obesity (289)
Opinion (164)
Ovarian cancer (168)
Pain (191)
Pancreatic cancer (208)
Parkinson's disease (257)
Partnered (29)
Patents (484)
Patient recruitment (530)
Peanut (43)
People (39523)
Pharmaceutical (18)
Pharmacy benefit managers (12)
Phase 1 (13285)
Phase 2 (16794)
Phase 3 (11699)
Pipeline (7293)
Policy (128)
Postmarket research (855)
Preclinical (5950)
Press Release (72)
Prostate cancer (220)
Psychedelics (14)
Radiopharmaceuticals (257)
Rare diseases (944)
Real estate (3925)
Recruiting (31)
Regulatory (14895)
Reports (29)
Research institute (1715)
Resumes & cover letters (79)
Rett syndrome (48)
RNA editing (25)
RSV (57)
Schizophrenia (56)
Series A (248)
Series B (166)
Service/supplier (5)
Sickle cell disease (114)
Special edition (10)
Spinal muscular atrophy (157)
Sponsored (34)
Startups (2890)
State (2)
Stomach cancer (9)
Supply chain (80)
Tariffs (26)
The Weekly (75)
Vaccines (723)
Venture capital (81)
Weight loss (125)
Women's health (89)
Worklife (4)
Date
Today (49)
Last 7 days (251)
Last 30 days (1555)
Last 365 days (18566)
2026 (12362)
2025 (18620)
2024 (22444)
2023 (26348)
2022 (35858)
2021 (37931)
2020 (35797)
2019 (29567)
2018 (22124)
2017 (21993)
2016 (20575)
2015 (23938)
2014 (17999)
2013 (22635)
2012 (16297)
2011 (16551)
2010 (15163)
Location
Africa (404)
Alabama (82)
Alaska (6)
Arizona (262)
Arkansas (12)
Asia (37111)
Australia (5687)
California (8579)
Canada (2465)
China (1196)
Colorado (409)
Connecticut (402)
Delaware (188)
Europe (65546)
Florida (1441)
Georgia (293)
Hawaii (3)
Idaho (36)
Illinois (760)
India (90)
Indiana (386)
Iowa (16)
Japan (559)
Kansas (115)
Kentucky (33)
Louisiana (38)
Maine (28)
Maryland (1076)
Massachusetts (6036)
Michigan (352)
Minnesota (561)
Mississippi (6)
Missouri (135)
Montana (29)
Nebraska (18)
Nevada (71)
New Hampshire (89)
New Jersey (2419)
New Mexico (24)
New York (2217)
North Carolina (1143)
North Dakota (11)
Northern California (4022)
Ohio (342)
Oklahoma (22)
Oregon (29)
Pennsylvania (1729)
Puerto Rico (26)
Rhode Island (46)
South America (622)
South Carolina (85)
South Dakota (1)
Southern California (3668)
Tennessee (150)
Texas (1475)
United States (31352)
Utah (291)
Vermont (2)
Virginia (183)
Washington D.C. (22)
Washington State (738)
West Virginia (3)
Wisconsin (135)
Wyoming (2)
462,856 Results for "oxford gene technology ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
New England Biolabs® launches the NEBNext® Companion Module for Oxford Nanopore Technologies® Direct RNA Sequencing
July 7, 2026
·
2 min read
Press Releases
Visionary Holdings’ Subsidiary Nanjing Tuoyuanjian Health Technology Co., Ltd. Enters into Distribution Agreement with Suncare (Shanghai) Health Technology Co., Ltd.
Collaboration Expected to Expand the Commercialization of Stem Cell Aesthetic and Anti-Aging Products Through an AI-Enabled Community Healthcare and Senior Care Network in China
July 29, 2026
·
4 min read
Mergers & acquisitions
Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal
After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.
April 20, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
·
5 min read
Press Releases
Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026
July 13, 2026
·
6 min read
Gene Therapy
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis.
August 7, 2026
·
2 min read
·
Tristan Manalac
Opinion
Assessing shared failures with AI is key to cell and gene therapy’s evolution
If we guard our secrets, patients suffer. Only through a commitment to transparency and data sharing—and artificial intelligence—can we make cell and gene therapies safer and more effective.
August 18, 2026
·
5 min read
·
Alexander Seyf
Gene therapy
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.
August 20, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
July 16, 2026
·
5 min read
Neuroscience
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’
As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
June 22, 2026
·
3 min read
·
Tristan Manalac
1 of 46,286
Next
